Anticoagulation in Non-valvular Atrial Fibrillation

**CHA\(\text{DS}_2\)-VASc Scoring Tool**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congestive heart failure</td>
<td>1</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1</td>
</tr>
<tr>
<td>Age &gt; 75 years</td>
<td>2</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1</td>
</tr>
<tr>
<td>Stroke/TIA or thromboembolism (prior)</td>
<td>2</td>
</tr>
<tr>
<td>Vascular disease (MI, PAD, or aortic plaque)</td>
<td>1</td>
</tr>
<tr>
<td>Age 65-74 years</td>
<td>1</td>
</tr>
</tbody>
</table>

**Score**

- 0: Low
- 1: Intermediate
- 2: High
- 3: Extra High

**2019 AHA / ACC Recommendation**

- 0: No treatment
- 1: Anticoagulate (men and women)
- 2: Consider (men)
- 3: Consider oral anticoagulant in men

**Yearly Stroke Risk (%)**

- 0: 0
- 1: 0.5
- 2: 0.8
- 3: 1.1
- 4: 1.4
- 5: 2.3
- 6: 3.4

**For additional information about anticoagulation in Atrial Fibrillation, visit**

www.anticoagulationtoolkit.org
References


Drug package inserts
- Apixaban: https://packageinserts.bms.com/pi/pi_eliquis.pdf
- Dabigatran: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf
- Edoxaban: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true

Disclaimer: This document is for informational purposes only and does not, itself, constitute medical advice. This document is not a replacement for careful medical judgments by qualified medical personnel. There may be information in this document that does not apply to or may be inappropriate for the medical situation at hand.